During the past decade, Dayton Center for Neurological Disorders conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 3 clinical trials were completed, i.e. on average, 21.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dayton Center for Neurological Disorders" #1 sponsor was "ACADIA Pharmaceuticals Inc." with 2 trials, followed by "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "AEON Biopharma, Inc." with 1 trials sponsored and "Allergan" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dayton Center for Neurological Disorders" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "EMD Serono" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Dayton Center for Neurological Disorders" are "Alzheimer Disease" (3 trials), "Migraine" (2 trials), "Multiple Sclerosis" (2 trials), "Adult Lower Limb Spasticity" (1 trials) and "Alzheimer's Disease" (1 trials). Many other conditions were trialed in "Dayton Center for Neurological Disorders" in a lesser frequency.

Most popular intervention types in "Dayton Center for Neurological Disorders" are "Drug" (16 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Cladribine Tablets" (2 trials), "ABP-450" (1 trials), "Active Investigational Treatment ENT-01" (1 trials) and "Droxidopa capsules" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dayton Center for Neurological Disorders" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Dayton Center for Neurological Disorders". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Dayton Center for Neurological Disorders, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Dayton Center for Neurological Disorders, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".